DiaMedica Therapeutics Inc (DMAC)vsRevolution Medicines Inc (RVMD)
DMAC
DiaMedica Therapeutics Inc
$8.33
-5.23%
HEALTHCARE · Cap: $474.29M
RVMD
Revolution Medicines Inc
$166.87
-3.15%
HEALTHCARE · Cap: $41.76B
Smart Verdict
WallStSmart Research — data-driven comparison
RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 23/100 (F).
DMAC
Avoid20
out of 100
Grade: F
RVMD
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for DMAC.
Margin of Safety
+89.8%
Fair Value
$1883.88
Current Price
$166.87
$1717.01 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Areas to Watch
Trading at 15.7x book value
0.0% revenue growth
0.0% earnings growth
Distress zone — elevated risk
Trading at 15.0x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : DMAC
The strongest argument for DMAC centers on Debt/Equity.
Bull Case : RVMD
The strongest argument for RVMD centers on Debt/Equity.
Bear Case : DMAC
The primary concerns for DMAC are Price/Book, Revenue Growth, EPS Growth.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD carries more volatility with a beta of 1.43 — expect wider price swings.
DMAC is growing revenue faster at 0.0% — sustainability is the question.
DMAC generates stronger free cash flow (-8M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (23/100 vs 20/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
DiaMedica Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company is headquartered in Minneapolis, Minnesota.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?